Buchumschlag

Response to first-line treatment with immune-checkpoint inhibitors in patients with advanced cutaneous squamous cell carcinoma: a multicenter, retrospective analysis from the German ADOReg registry

Cutaneous squamous cell carcinoma (cSCC) is a common malignancy of the skin and has an overall favorable outcome, except for patients with an advanced stage of the disease. The efficacy of checkpoint inhibitors (CPI) for advanced cSCC has been demonstrated in recent clinical studies, but data from r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Haist, Maximilian (VerfasserIn) , Stege, Henner (VerfasserIn) , Lang, Berenice Mareen (VerfasserIn) , Tsochataridou, Aikaterini (VerfasserIn) , Salzmann, Martin (VerfasserIn) , Mohr, Peter (VerfasserIn) , Schadendorf, Dirk (VerfasserIn) , Ugurel, Selma (VerfasserIn) , Placke, Jan-Malte (VerfasserIn) , Weichenthal, Michael (VerfasserIn) , Gutzmer, Ralf (VerfasserIn) , Leiter, Ulrike (VerfasserIn) , Kaatz, Martin (VerfasserIn) , Haferkamp, Sebastian (VerfasserIn) , Berking, Carola (VerfasserIn) , Heppt, Markus V. (VerfasserIn) , Tschechne, Barbara (VerfasserIn) , Schummer, Patrick (VerfasserIn) , Gebhardt, Christoffer (VerfasserIn) , Grabbe, Stephan (VerfasserIn) , Loquai, Carmen (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 11 November 2022
In: Cancers
Year: 2022, Jahrgang: 14, Heft: 22, Pages: 1-14
ISSN:2072-6694
DOI:10.3390/cancers14225543
Online-Zugang:Resolving-System, Volltext: https://doi.org/10.3390/cancers14225543
Verlag, Volltext: https://www.mdpi.com/2072-6694/14/22/5543
Volltext
Verfasserangaben:Maximilian Haist, Henner Stege, Berenice Mareen Lang, Aikaterini Tsochataridou, Martin Salzmann, Peter Mohr, Dirk Schadendorf, Selma Ugurel, Jan-Malte Placke, Michael Weichenthal, Ralf Gutzmer, Ulrike Leiter, Martin Kaatz, Sebastian Haferkamp, Carola Berking, Markus Heppt, Barbara Tschechne, Patrick Schummer, Christoffer Gebhardt, Stephan Grabbe and Carmen Loquai
Beschreibung
Zusammenfassung:Cutaneous squamous cell carcinoma (cSCC) is a common malignancy of the skin and has an overall favorable outcome, except for patients with an advanced stage of the disease. The efficacy of checkpoint inhibitors (CPI) for advanced cSCC has been demonstrated in recent clinical studies, but data from real-world cohorts and trial-ineligible cSCC patients are limited. We retrospectively investigated patients with advanced cSCC who have been treated with CPI in a first-line setting at eight German skin cancer centers registered within the multicenter registry ADOReg. Clinical outcome parameters including response, progression-free (PFS) and overall survival (OS), time-to-next-treatment (TTNT), and toxicity were analyzed and have been stratified by the individual immune status.
Beschreibung:Gesehen am 26.01.2023
Beschreibung:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers14225543

Ähnliche Einträge